1. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Issue 4 (April 2016) Authors: Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Jürgen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, S... Journal: Lancet oncology Issue: Volume 17:Issue 4(2016:Apr.) Page Start: 452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Issue 12 (December 2021) Authors: Lakhani, Nehal J; Chow, Laura Q M; Gainor, Justin F; LoRusso, Patricia; Lee, Keun-Wook; Chung, Hyun Cheol; Lee, Jeeyun; Bang, Yung-Jue; Hodi, Frank Stephen; Kim, Won Seog; Santana-Davila, Rafael; Fanning, Philip; Squifflet, Pierre; Jin, Feng; Kuo, Tracy C; Wan, Hong I; Pons, Jaume; Randolph, Soph... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1740 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Issue 10 (October 2019) Authors: Antonia, Scott J; Borghaei, Hossein; Ramalingam, Suresh S; Horn, Leora; De Castro Carpeño, Javier; Pluzanski, Adam; Burgio, Marco A; Garassino, Marina; Chow, Laura Q M; Gettinger, Scott; Crinò, Lucio; Planchard, David; Butts, Charles; Drilon, Alexander; Wojcik-Tomaszewska, Joanna; Otterson, Grego... Journal: Lancet oncology Issue: Volume 20:Issue 10(2019) Page Start: 1395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Issue 2 (25th February 2022) Authors: Haddad, Robert I; Seiwert, Tanguy Y; Chow, Laura Q M; Gupta, Shilpa; Weiss, Jared; Gluck, Iris; Eder, Joseph P; Burtness, Barbara; Tahara, Makoto; Keam, Bhumsuk; Kang, Hyunseok; Muro, Kei; Albright, Andrew; Mogg, Robin; Ayers, Mark; Huang, Lingkang; Lunceford, Jared; Cristescu, Razvan; Cheng, Jon... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Issue 2 (February 2017) Authors: Plimack, Elizabeth R; Bellmunt, Joaquim; Gupta, Shilpa; Berger, Raanan; Chow, Laura Q M; Juco, Jonathan; Lunceford, Jared; Saraf, Sanatan; Perini, Rodolfo F; O'Donnell, Peter H Journal: Lancet oncology Issue: Volume 18:Issue 2(2017:Feb.) Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study. Issue 3 (23rd March 2020) Authors: Al Achkar, Morhaf; Marchand, Lucille; Thompson, Matthew; Chow, Laura Q M; Revere, Debra; Baldwin, Laura-Mae Journal: BMJ open Issue: Volume 10:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗